We’re extremely pleased that the FDA has formally accepted the MelaFind PMA for review. This brings us one step closer to realizing our goal of offering clinicians a reliable tool to help them to detect melanoma while it is still in its earliest, most curable stages, said Joseph V. Gulfo, M.D., President and CEO. We look forward to advancing our discussions with the FDA and obtaining the agency’s feedback on the MelaFind PMA and next steps in the review process.
